The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation : a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease

Detalhes bibliográficos
Autor(a) principal: Souliotis, Kyriakos
Data de Publicação: 2020
Outros Autores: Miguel, Luís Lopes Madureira Silva, Hillas, Georgios, Borges, Margarida, Papageorgiou, Giannis, Viana, Diogo, Malhadeiro, Joao, Soulard, Stéphane
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/43842
Resumo: Conflict of interest statement KS, LSM, GH and MB received grants from Boehringer Ingelheim. GP, DV, JM and SS are employed by Boehringer Ingelheim.
id RCAP_a4da42d53bc07b0ebc0f2cfbd7e8f7b0
oai_identifier_str oai:repositorio.ul.pt:10451/43842
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation : a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary diseaseBudget impact analysisCOPDDiabetesExacerbationGreecePneumoniaPortugalConflict of interest statement KS, LSM, GH and MB received grants from Boehringer Ingelheim. GP, DV, JM and SS are employed by Boehringer Ingelheim.© Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Purpose: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018 recommendations support maintenance treatment with long-acting bronchodilators in most symptomatic patients with chronic obstructive pulmonary disease (COPD). While restricting the overuse of inhaled corticosteroids (ICS) may influence healthcare utilization required to treat inadvertent respiratory (exacerbations and pneumonia) and diabetes-related events, it may also change the total medication cost. This analysis was performed to estimate the 5-year budget impact of switching from ICS-containing treatment combinations to dual bronchodilation, in line with the recommendations. Methods: The model quantified the budget impact of treatment and healthcare resource utilization when COPD patients were anticipated to switch from ICS-containing treatments to dual bronchodilation. Three switch scenarios were calculated with increasing proportions of patients on dual long-acting bronchodilators, to the detriment of ICS-containing double and triple combinations. Clinical and cost input data were based on results from clinical trials and Greek and Portuguese healthcare cost databases. Results: Healthcare resource use to manage exacerbations, pneumonia and diabetes-related events were projected to increase between 2019 and 2023 in parallel with the growing COPD patient population and associated costs were estimated at 52–57% of the total disease cost in the Greek and Portuguese base case scenarios. Total cost savings between 21 and 112million EUR were projected when the proportion of patients on double and triple ICS-containing treatments was gradually reduced to 50% in scenario A, 20% in scenario B and 7% in scenario C. Sensitivity analyses showed that none of the model assumptions had a major impact on the projected savings. Conclusion: The alignment of COPD treatment with current recommendations may bring clinical benefits to patients, without substantial cost increases and even cost savings for payers.The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded by Boehringer Ingelheim.SAGE PublicationsRepositório da Universidade de LisboaSouliotis, KyriakosMiguel, Luís Lopes Madureira SilvaHillas, GeorgiosBorges, MargaridaPapageorgiou, GiannisViana, DiogoMalhadeiro, JoaoSoulard, Stéphane2020-06-17T10:30:21Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/43842engTher Adv Respir Dis 2020, Vol. 14: 1–131753-465810.1177/17534666209268021753-4666info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:44:31Zoai:repositorio.ul.pt:10451/43842Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:56:35.397171Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation : a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease
title The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation : a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease
spellingShingle The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation : a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease
Souliotis, Kyriakos
Budget impact analysis
COPD
Diabetes
Exacerbation
Greece
Pneumonia
Portugal
title_short The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation : a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease
title_full The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation : a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease
title_fullStr The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation : a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease
title_full_unstemmed The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation : a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease
title_sort The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation : a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease
author Souliotis, Kyriakos
author_facet Souliotis, Kyriakos
Miguel, Luís Lopes Madureira Silva
Hillas, Georgios
Borges, Margarida
Papageorgiou, Giannis
Viana, Diogo
Malhadeiro, Joao
Soulard, Stéphane
author_role author
author2 Miguel, Luís Lopes Madureira Silva
Hillas, Georgios
Borges, Margarida
Papageorgiou, Giannis
Viana, Diogo
Malhadeiro, Joao
Soulard, Stéphane
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Souliotis, Kyriakos
Miguel, Luís Lopes Madureira Silva
Hillas, Georgios
Borges, Margarida
Papageorgiou, Giannis
Viana, Diogo
Malhadeiro, Joao
Soulard, Stéphane
dc.subject.por.fl_str_mv Budget impact analysis
COPD
Diabetes
Exacerbation
Greece
Pneumonia
Portugal
topic Budget impact analysis
COPD
Diabetes
Exacerbation
Greece
Pneumonia
Portugal
description Conflict of interest statement KS, LSM, GH and MB received grants from Boehringer Ingelheim. GP, DV, JM and SS are employed by Boehringer Ingelheim.
publishDate 2020
dc.date.none.fl_str_mv 2020-06-17T10:30:21Z
2020
2020-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/43842
url http://hdl.handle.net/10451/43842
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Ther Adv Respir Dis 2020, Vol. 14: 1–13
1753-4658
10.1177/1753466620926802
1753-4666
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134507942543360

Registros relacionados